+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Therapeutic BCG Vaccine Market by Vaccine Type, Indication, Route of Administration, Treatment Regimen, End User - Global Forecast 2026-2032- Product Image
Therapeutic BCG Vaccine Market by Vaccine Type, Indication, Route of Administration, Treatment Regimen, End User - Global Forecast 2026-2032- Product Image
Sale

Therapeutic BCG Vaccine Market by Vaccine Type, Indication, Route of Administration, Treatment Regimen, End User - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4986049
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Therapeutic BCG Vaccine Market is projected to reach USD 374.49 Million in 2026. It is expected to continue growing at a CAGR of 5.29%, reaching USD 511.15 Million by 2032.

Therapeutic BCG vaccine remains the backbone of adjuvant immunotherapy for high-risk non-muscle-invasive bladder cancer (NMIBC), particularly carcinoma in situ and high-grade Ta/T1 disease following transurethral resection of bladder tumor. Unlike prophylactic BCG used for tuberculosis prevention, therapeutic BCG is administered intravesically to stimulate localized immune activity against malignant urothelial cells.

The demand foundation is clinically durable and epidemiologically significant. IARC GLOBOCAN 2022 estimated approximately 614,000 new bladder cancer cases and more than 220,000 bladder cancer deaths worldwide, with incidence concentrated among older adults and substantially higher in men. For pharmaceutical and biotechnology manufacturers, the therapeutic BCG vaccine landscape is shaped by persistent need for BCG supply reliability, optimized strains, improved administration schedules, and evidence-based alternatives for BCG-unresponsive disease.

Transformative Shifts in the Therapeutic BCG Landscape

The therapeutic BCG vaccine landscape is being reshaped by three verified forces: global BCG supply constraints, stricter clinical definitions of BCG-unresponsive NMIBC, and rapid expansion of bladder-sparing treatment innovation. Major urology guidelines continue to recommend induction and maintenance BCG for eligible high-risk NMIBC, but shortages have led to dose prioritization, reduced-dose protocols, and greater use of intravesical chemotherapy in selected cases.

For manufacturers, this creates a dual opportunity. Established producers can strengthen competitive positioning through resilient biologics manufacturing, strain consistency, cold-chain excellence, and regulatory-grade quality systems. Emerging developers can compete through recombinant BCG platforms, immune-enhancing combinations, and next-generation intravesical therapies designed to address recurrence, tolerability, and progression risk.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to affect the cumulative economics of therapeutic BCG vaccine development and commercialization across discovery, manufacturing, clinical operations, and pharmacovigilance. In research and development, machine learning can support biomarker discovery, immune-response profiling, patient stratification, and trial enrichment for BCG-responsive versus BCG-unresponsive NMIBC populations.

In manufacturing, AI-enabled process analytics can improve batch monitoring for live biotherapeutic products, identify deviations earlier, and support predictive maintenance in GMP facilities. In commercialization, AI can improve demand planning during shortage conditions, align allocation with clinical priority, and analyze real-world evidence from electronic health records and registries while preserving compliance with privacy and pharmacovigilance requirements.

Key Regional Insights

Asia-Pacific represents a major long-term opportunity because China, India, Japan, South Korea, and Australia combine large aging populations with expanding urology infrastructure and growing oncology access. China and Japan are especially important due to high absolute bladder cancer burden and established hospital-based cancer care, while India is advancing access through broader oncology capacity and public health insurance expansion. South Korea and Australia add advanced diagnostic capacity, specialist urology networks, and strong regulatory expectations for quality and safety monitoring.

North America remains one of the most commercially advanced regions for therapeutic BCG vaccine adoption because the United States and Canada have strong guideline implementation, high cystoscopy utilization, mature reimbursement systems, and early uptake of therapies for BCG-unresponsive NMIBC. Europe benefits from harmonized clinical standards across major markets and broad access to specialist urologic oncology, although procurement, pricing, and national reimbursement pathways vary. Latin America, led by Brazil and Mexico, shows rising demand for intravesical immunotherapy but remains constrained by uneven access to specialist urology services, fragmented reimbursement, and regional disparities in cancer diagnosis. The Middle East, particularly GCC health systems, is investing in oncology infrastructure, tertiary hospitals, and centralized procurement, while Africa faces the greatest access challenges due to diagnostic limitations, constrained cold-chain capacity, later-stage cancer presentation, and lower availability of specialist bladder cancer care.

Key Group Insights

ASEAN markets present a practical growth corridor for therapeutic BCG vaccine manufacturers as cancer centers in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expand diagnostic and urologic oncology services. Commercial success across ASEAN depends on cold-chain reliability, clinician education, hospital tender access, and public-private procurement models that support consistent product availability.

The GCC offers a high-investment healthcare environment where national cancer strategies, centralized procurement, tertiary hospitals, and growing medical tourism capacity can accelerate adoption of guideline-based NMIBC treatment. The European Union remains a highly regulated but attractive bloc due to clinical standardization, pharmacovigilance requirements, and biologics oversight under regional and national authorities. BRICS countries are strategically important because China, India, Brazil, Russia, and South Africa combine large patient pools with cost-sensitive access needs and increasing emphasis on domestic healthcare capacity. G7 and NATO-aligned markets generally offer strong regulatory predictability, mature pharmacovigilance expectations, established oncology infrastructure, and higher readiness for AI-supported evidence generation and supply-chain resilience.

Key Country Insights

The United States is the pivotal country market due to high guideline penetration, strong academic urology networks, broad cystoscopy access, and recognized regulatory pathways for BCG-unresponsive NMIBC alternatives. Canada follows similar clinical standards but with provincial reimbursement dynamics and centralized health technology assessment considerations. Mexico and Brazil offer growth potential driven by large populations and expanding cancer care, though access remains uneven across public and private systems and specialist availability varies by region.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have sophisticated urology systems and established intravesical therapy use, while Russia presents a sizable but more complex regulatory and procurement environment. China and India are central to future volume growth because of population scale, increasing bladder cancer detection, and expanding oncology infrastructure. Japan and South Korea are advanced, quality-sensitive markets with strong clinical adoption capacity, aging populations, and high expectations for post-treatment surveillance. Australia offers a smaller but well-regulated market with high standards for evidence, safety monitoring, and specialist care delivery.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturing redundancy, validated strain control, and geographically diversified supply to reduce vulnerability to recurring BCG shortages. Companies should also invest in real-world evidence programs that measure recurrence-free survival, progression, adverse events, treatment completion, retreatment patterns, and outcomes after reduced-dose schedules.

Strategically, manufacturers should develop differentiated portfolios that include therapeutic BCG, recombinant or enhanced BCG candidates, and combination regimens for high-risk and BCG-unresponsive NMIBC. Partnerships with urology networks, cancer registries, contract manufacturers, and AI-enabled quality analytics vendors can improve evidence generation, access planning, pharmacovigilance, and operational resilience.

Research Methodology

This executive summary is built on secondary research from verified public-domain and regulatory sources, including IARC GLOBOCAN cancer statistics, WHO and national cancer resources, urology guideline bodies, regulatory approval databases, peer-reviewed oncology literature, and established clinical trial registries. The analysis emphasizes therapeutic BCG use in NMIBC and differentiates it from prophylactic tuberculosis vaccination.

Research inputs were triangulated across epidemiology, clinical guidelines, regulatory decisions, regional healthcare access indicators, biologics manufacturing considerations, and real-world evidence priorities. Insights were synthesized to support market interpretation while avoiding unsupported market-size claims, market-share estimates, or unverified projections.

Conclusion

Therapeutic BCG vaccine continues to occupy a critical position in bladder cancer care because it combines decades of clinical use with guideline-backed relevance in high-risk NMIBC. However, supply constraints, changing treatment algorithms, and rising expectations for BCG-unresponsive disease are redefining competitive advantage.

Manufacturers that combine robust biologics production, data-driven quality systems, clinical evidence generation, and regional access strategies will be best positioned to capture demand. The next phase of industry development will favor organizations that protect BCG availability while advancing more precise, tolerable, and durable intravesical immunotherapy solutions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Therapeutic BCG Vaccine Market, by Vaccine Type
7.1. Standard BCG Vaccine
7.2. Modified BCG Vaccines
7.3. Next-Generation BCG-Based Immunotherapies
8. Therapeutic BCG Vaccine Market, by Indication
8.1. Non-muscle Invasive Bladder Cancer
8.2. Tuberculosis
8.3. Autoimmune & Infectious Diseases
9. Therapeutic BCG Vaccine Market, by Route of Administration
9.1. Intravesical Administration
9.2. Intradermal Administration
9.3. Intravenous
10. Therapeutic BCG Vaccine Market, by Treatment Regimen
10.1. Induction Therapy
10.2. Maintenance Therapy
10.3. Combination Therapy Regimens
11. Therapeutic BCG Vaccine Market, by End User
11.1. Hospitals
11.2. Oncology Centers
11.3. Specialty Clinics
11.4. Research Institutes
12. Asia-Pacific Therapeutic BCG Vaccine Market
13. Europe Therapeutic BCG Vaccine Market
14. North America Therapeutic BCG Vaccine Market
15. Latin America Therapeutic BCG Vaccine Market
16. Africa Therapeutic BCG Vaccine Market
17. Middle East Therapeutic BCG Vaccine Market
18. NATO Therapeutic BCG Vaccine Market
19. G7 Therapeutic BCG Vaccine Market
20. BRICS Therapeutic BCG Vaccine Market
21. European Union Therapeutic BCG Vaccine Market
22. ASEAN Therapeutic BCG Vaccine Market
23. GCC Therapeutic BCG Vaccine Market
24. China Therapeutic BCG Vaccine Market
25. United States Therapeutic BCG Vaccine Market
26. Japan Therapeutic BCG Vaccine Market
27. India Therapeutic BCG Vaccine Market
28. Germany Therapeutic BCG Vaccine Market
29. United Kingdom Therapeutic BCG Vaccine Market
30. Australia Therapeutic BCG Vaccine Market
31. France Therapeutic BCG Vaccine Market
32. South Korea Therapeutic BCG Vaccine Market
33. Italy Therapeutic BCG Vaccine Market
34. Canada Therapeutic BCG Vaccine Market
35. Russia Therapeutic BCG Vaccine Market
36. Brazil Therapeutic BCG Vaccine Market
37. Mexico Therapeutic BCG Vaccine Market
38. Spain Therapeutic BCG Vaccine Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. AJ Vaccines A/S
40.2. Bharat Biotech International Limited
40.3. Biofabri
40.4. BioFarma
40.5. Biological E. Limited
40.6. Biomed Lublin S.A.
40.7. Bul Bio-NCIPD Ltd.
40.8. China National Biotec Group
40.9. GlaxoSmithKline plc
40.10. GreenSignal Bio Pharma Ltd.
40.11. ImmunityBio, Inc.
40.12. Indian Immunologicals Limited
40.13. Instituto Butantan
40.14. InterVax Ltd.
40.15. Japan BCG Laboratory
40.16. Laboratorios Reig Jofre S.A.
40.17. Merck & Co., Inc.
40.18. Microgen (NPO Microgen)
40.19. Panacea Biotec Ltd.
40.20. Sanofi
40.21. Serum Institute of India Pvt. Ltd.
40.22. Shanghai Institute of Biological Products Co., Ltd.
40.23. Statens Serum Institut
40.24. Taj Pharmaceuticals Limited
40.25. Torlak Institute of Virology
List of Figures
FIGURE 1. GLOBAL THERAPEUTIC BCG VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL THERAPEUTIC BCG VACCINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL THERAPEUTIC BCG VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL THERAPEUTIC BCG VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2032 (%)
FIGURE 21. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL THERAPEUTIC BCG VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL THERAPEUTIC BCG VACCINE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL THERAPEUTIC BCG VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL STANDARD BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL STANDARD BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL STANDARD BCG VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MODIFIED BCG VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MODIFIED BCG VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MODIFIED BCG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEXT-GENERATION BCG-BASED IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEXT-GENERATION BCG-BASED IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEXT-GENERATION BCG-BASED IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL AUTOIMMUNE & INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL AUTOIMMUNE & INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AUTOIMMUNE & INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INTRAVESICAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INTRAVESICAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL INTRAVESICAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL INTRADERMAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INDUCTION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INDUCTION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL INDUCTION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MAINTENANCE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL COMBINATION THERAPY REGIMENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL COMBINATION THERAPY REGIMENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL COMBINATION THERAPY REGIMENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ONCOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 63. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 64. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 67. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 69. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 70. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 72. EUROPE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 85. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 87. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 88. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 89. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 90. AFRICA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 93. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 94. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 99. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 100. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 101. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 102. NATO THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 105. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 108. G7 THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 111. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 112. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 114. BRICS THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 117. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 118. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 123. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 124. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 126. ASEAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 129. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 130. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 131. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 132. GCC THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 134. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 135. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 136. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 137. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 138. CHINA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 140. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 141. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 142. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 144. UNITED STATES THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 146. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 147. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 148. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 150. JAPAN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 152. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 153. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 156. INDIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 157. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 158. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 159. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 160. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 162. GERMANY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 164. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 165. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 166. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 168. UNITED KINGDOM THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 170. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 171. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 172. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 174. AUSTRALIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 176. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 177. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 178. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 180. FRANCE THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 182. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 183. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 184. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 186. SOUTH KOREA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 189. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 190. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 192. ITALY THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 194. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 195. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 196. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 197. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 198. CANADA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 199. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 200. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 201. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 202. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 204. RUSSIA THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 206. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 207. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 208. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 210. BRAZIL THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 213. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 214. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 216. MEXICO THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
TABLE 219. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 220. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
TABLE 222. SPAIN THERAPEUTIC BCG VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Therapeutic BCG Vaccine market report include:
  • AJ Vaccines A/S
  • Bharat Biotech International Limited
  • Biofabri
  • BioFarma
  • Biological E. Limited
  • Biomed Lublin S.A.
  • Bul Bio-NCIPD Ltd.
  • China National Biotec Group
  • GlaxoSmithKline plc
  • GreenSignal Bio Pharma Ltd.
  • ImmunityBio, Inc.
  • Indian Immunologicals Limited
  • Instituto Butantan
  • InterVax Ltd.
  • Japan BCG Laboratory
  • Laboratorios Reig Jofre S.A.
  • Merck & Co., Inc.
  • Microgen (NPO Microgen)
  • Panacea Biotec Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Statens Serum Institut
  • Taj Pharmaceuticals Limited
  • Torlak Institute of Virology

Table Information

Report AttributeDetails
No. of Pages196
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 374.49 Million
Forecasted Market Value ( USD ) by 2032 $ 511.15 Million
Compound Annual Growth Rate5.2%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Therapeutic Bcg Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Therapeutic Bcg Vaccines Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
BCG Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

BCG Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Therapeutic BCG Vaccines Market Report 2026 - Product Image

Therapeutic BCG Vaccines Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Bacillus Calmette-Guérin (BCG) Vaccines - Global Strategic Business Report - Product Image

Bacillus Calmette-Guérin (BCG) Vaccines - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From
BCG Vaccine Market Outlook 2026-2034: Market Share and Growth Analysis by Age Group (Paediatric, Adults), Application, Distribution Channel - Product Image

BCG Vaccine Market Outlook 2026-2034: Market Share and Growth Analysis by Age Group (Paediatric, Adults), Application, Distribution Channel

  • Report
  • 160 Pages
  • Global
From

About the Market

The BCG Vaccine is a vaccine used to protect against tuberculosis (TB). It is the only vaccine available for TB prevention and is used in many countries around the world. The BCG Vaccine market is a subset of the larger Vaccines market, which includes a wide range of vaccines used to prevent and treat various diseases. The BCG Vaccine market is largely driven by the prevalence of TB in different countries, as well as the availability of the vaccine. The BCG Vaccine market is highly competitive, with many companies offering the vaccine. Some of the major players in the market include Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Pfizer, and Serum Institute of India. Other companies in the market include Emergent BioSolutions, Bavarian Nordic, and Valneva. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.